(MedPage Today) — CHICAGO — For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields (TTFields).
Median OS increased…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115869
Author :
Publish date : 2025-06-02 21:31:00
Copyright for syndicated content belongs to the linked Source.